Bioventix PLC (LON:BVXP - Get Free Report) insider Bruce Hiscock purchased 31 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was acquired at an average price of GBX 2,632 ($35.36) per share, for a total transaction of £815.92 ($1,096.22).
Bioventix Trading Down 0.1 %
Shares of LON:BVXP opened at GBX 2,586.50 ($34.75) on Tuesday. Bioventix PLC has a twelve month low of GBX 2,200 ($29.56) and a twelve month high of GBX 4,550 ($61.13). The company's 50 day moving average is GBX 2,665.01 and its 200 day moving average is GBX 3,153.14. The company has a market cap of £135.44 million, a PE ratio of 16.73 and a beta of 0.35.
Bioventix (LON:BVXP - Get Free Report) last issued its quarterly earnings results on Monday, March 31st. The biotechnology company reported GBX 72.27 ($0.97) earnings per share for the quarter. Bioventix had a net margin of 59.51% and a return on equity of 69.09%. Equities research analysts predict that Bioventix PLC will post 166.3066955 earnings per share for the current fiscal year.
Bioventix Cuts Dividend
The firm also recently declared a dividend, which was paid on Friday, April 25th. Investors of record on Thursday, April 10th were issued a GBX 70 ($0.94) dividend. The ex-dividend date of this dividend was Thursday, April 10th. This represents a yield of 2.95%. Bioventix's dividend payout ratio (DPR) is presently 102.19%.
Bioventix Company Profile
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
